Allied Market Research

2024

Pediatric Drugs Market

Pediatric Drugs Market Size, Share, Competitive Landscape and Trend Analysis Report by Drug Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs, Other Drug Types), by Route of Administration (Oral, Topical, Parenteral, Other Routes of Administration) : Global Opportunity Analysis and Industry Forecast, 2022-2032

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Pediatric drugs are specifically designed and formulated for children, from newborns up to 18 years of age. Children have unique physiological and pharmacological characteristics, which make it essential to develop and test drugs that are safe and effective for them. Development of pediatric drugs has been historically challenging due to ethical and practical considerations. Children are vulnerable and the risks of testing drugs on them need to be balanced against the potential benefits. In addition, children may have different responses to drugs than adults due to differences in their body size, organ function, and metabolic rate.
To encourage development of safe and effective pediatric drugs, regulatory agencies around the world have established guidelines and initiatives that provide incentives and support to pharmaceutical companies to conduct research and development of pediatric drugs. These initiatives include the Pediatric Research Equity Act (PREA) in the U.S., which requires pharmaceutical companies to study the safety and efficacy of their drugs in children when the drug is also being studied in adults. Development of pediatric drugs is crucial for treating childhood illnesses and improving child health outcomes. Many drugs used in children today are off-label or have not been adequately tested in children, which can lead to unexpected side effects or ineffective treatments. Developing pediatric drugs ensures that children receive safe and effective treatments for their specific medical needs.
Common pediatric drugs include antibiotics, asthma medications, and medications for attention deficit hyperactivity disorder (ADHD), among others. These drugs are formulated and dosed to suit the unique needs of children and are often available in liquid or chewable form to make administration easier. 
In recent years, there has been a growing awareness among parents and healthcare professionals about the importance of child healthcare. This has resulted in an increase in number of children being diagnosed and treated for various health conditions, which has driven the growth of the pediatric drugs market.
Parents are becoming more aware of the importance of preventative healthcare and regular check-ups for their children. They are also more likely to seek medical advice and treatment for their children when they notice signs of illness or health issues. This increased awareness has led to earlier detection and diagnosis of health conditions in children, which in turn has increased the demand for pediatric drugs. Healthcare professionals are also contributing to this trend by educating parents and caregivers about the importance of child healthcare. They are providing more resources and information to help parents make informed decisions about their child's health, and are also actively diagnosing and treating more children for various health conditions.
In addition, rise of social media and online health resources has made it easier for parents to access information and connect with other parents and healthcare professionals, which has further increased awareness about child healthcare. Overall, the growing awareness about child healthcare is a positive trend that is driving the growth of the pediatric drugs market. As more children are diagnosed and treated for various health conditions, the demand for effective and safe pediatric drugs is likely to continue to grow. 
Development of innovative pediatric formulations has been a key driver in growth of the pediatric drugs market. Traditionally, administering drugs to children has been a challenge due to difficulties in swallowing pills or tablets, unpleasant taste, and other issues related to the dosing and administration of medicines. However, the development of innovative pediatric formulations such as chewable tablets, oral suspensions, and flavored syrups has made it easier to administer drugs to children, which has increased their acceptance of treatment.
Chewable tablets are easy for children to take and can come in various flavors, making them more palatable. They are also available in a variety of dosages, making it easier for healthcare professionals to tailor the medication to the child's specific needs. Flavored syrups are another form of liquid medication that can be easily administered to children. They are often used for antibiotics, pain relievers, and cough and cold medications, and come in a range of flavors to suit different taste preferences. Overall, the development of innovative pediatric formulations has been a key driver of the growth in the pediatric drugs market, as it has made it easier to administer drugs to children, increased their acceptance of treatment, and improved medication compliance. 
 
New product launches to flourish in the market
In September 2022, Roche announced the launch of its new pediatric cancer drug, Polivy (polatuzumab vedotin-piiq), in the United States. Polivy is a CD79b-directed antibody-drug conjugate, and is indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma in pediatric patients. Moreover, in August 2022, Novartis announced the launch of its new pediatric asthma treatment, Atectura Breezhaler (indacaterol acetate/glycopyrronium bromide), in the European Union. Atectura Breezhaler is a long-acting beta2-agonist/long-acting muscarinic antagonist combination, and is indicated for the maintenance treatment of asthma in children aged 6 to 11 years. Furthermore, in May 2022, Eli Lilly and Company announced the approval of its new pediatric migraine treatment, Emgality (galcanezumab-gnlm), in the United States. Emgality is a calcitonin gene-related peptide (CGRP) antagonist, and is indicated for the preventive treatment of migraine in pediatric patients aged 6 to 17 years.
Segment Overview: 
By Drug Type: The pediatric drugs market is divided into Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs and Other Drug Types. Respiratory Disorder Drugs are drugs used to treat respiratory conditions such as asthma, bronchitis, and other lung diseases. Examples include inhaled corticosteroids, bronchodilators, and leukotriene modifiers. Autoimmune Disorder Drugs are drugs used to treat autoimmune disorders, which occur when the immune system attacks the body's own tissues. Examples include corticosteroids, immunosuppressants, and biologic therapies. Gastrointestinal Drugs are drugs used to treat digestive disorders such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), and peptic ulcer disease. Examples include proton pump inhibitors, H2 blockers, and anti-inflammatory drugs. Moreover, cardiovascular Drugs are drugs used to treat heart and blood vessel disorders, such as high blood pressure and congenital heart defects. Examples include angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and diuretics. Moreover, other drug types includes drugs used to treat a variety of other conditions, such as pain, infections, and neurological disorders. Examples include antibiotics, anticonvulsants, and analgesics.
 
By Route of Administration: The pediatric drugs market is divided into Oral, Topical, Parenteral, and Other Routes of Administration. Oral refers to drugs that are taken by mouth, such as tablets, capsules, syrups, or suspensions. When it comes to topical it refers to drugs that are applied to the skin, such as creams, ointments, or gels. Parenteral refers to drugs that are given by injection or infusion, such as intravenous (IV) or intramuscular (IM) injections. In addition, other routes include other less common routes of administration, such as inhalation or rectal suppositories. 
 
By Region: The Asia Pacific pediatric drugs market is one of the fastest-growing markets in the world, with a significant increase in demand for pediatric medicines over the past few years. Several factors have contributed to the growth of the market in the Asia Pacific region, including increasing healthcare expenditure, rising awareness about child health, and a growing incidence of chronic diseases in children. One of the key drivers of growth in the Asia Pacific pediatric drugs market is the increasing healthcare expenditure in the region. Many countries in the region, including China, India, and Japan, have been increasing their healthcare spending in recent years, which has resulted in a greater demand for healthcare products and services, including pediatric drugs.
 
In addition, there is a growing awareness among parents and healthcare professionals in the Asia Pacific region about the importance of child health. This has resulted in an increase in the number of children being diagnosed and treated for various health conditions, which in turn has driven demand for pediatric drugs. Another factor contributing to the growth of the Asia Pacific pediatric drugs market is the rising incidence of chronic diseases in children. Chronic diseases such as asthma, diabetes, and heart disease are becoming more common among children in the region, which has created a growing demand for drugs to treat these conditions.
 
Competitive analysis and profiles of the major players in the pediatric drugs market, such as BioMarin Pharmaceutical Inc., Horizon Therapeutics PLC, PTC Therapeutics Inc., Sumitomo Dainippon Pharma Co. Ltd, Gilead Sciences Inc., Jazz Pharmaceuticals Inc., Pfizer Inc., GlaxoSmithKline plc., Johnson & Johnson, and Boehringer Ingelheim International GmbH are included in the report. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the pediatric drugs market.  

Pediatric Drugs Market Report Highlights

Aspects Details
Pediatric Drugs Market By Drug Type
By Drug Type
  • Respiratory Disorder Drugs
  • Autoimmune Disorder Drugs
  • Gastrointestinal Drugs
  • Cardiovascular Drugs
  • Other Drug Types
Pediatric Drugs Market By Route of Administration
By Route of Administration
  • Oral
  • Topical
  • Parenteral
  • Other Routes of Administration
Pediatric Drugs Market By Region
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players
Key Market Players

Sumitomo Dainippon Pharma Co. Ltd, Gilead Sciences Inc., Jazz Pharmaceuticals Inc., Horizon Therapeutics PLC, Johnson & Johnson, Boehringer Ingelheim International GmbH, PTC Therapeutics Inc., GlaxoSmithKline plc, BioMarin Pharmaceutical Inc., Pfizer Inc.

Key Market Players

Novartis, Sanofi SA

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Pediatric Drugs Market

Global Opportunity Analysis and Industry Forecast, 2022-2032